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GENE THERAPY OF PARKINSON'S DISEASE 
Parkinson's disease (PD) is a disease that manifests itself as a chronic, 
progressive neurodegenerative disorder, most commonly recognized as the deep 
degeneration of dopamine neurons in the middle brain associated with severe 
motor symptoms. Pathways, complex pathologies and a wide range of symptoms 
of the central nervous system (CNS) and non-central nervous system [1]. The 
disease has the following symptoms: tremor, bradykinesia and muscle rigidity, 
disorder of walking and posture. In addition, about 50% of PD patients also 
demonstrate mediated by-front-end executive dysfunction, including lack of 
attention, low speed of mental processing, verbal disorder, work memory 
disturbances and impulsivity. Patients in the risk group may have the following 
factors: elderly, older age of onset of the disease, limited cognitive reserve, 
hallucinations, and prevailing dysfunctional stroke [2]. 
In the modern treatment of Parkinson's disease (PD), substitution therapy is 
used, namely dopamine, which does not stop the progression of the disease, and 
also causes various side effects. The field of gene therapy provides the means to 
improve current therapy. 
Patients who took the AXO-Lenti-PD vector for 3 months showed a 
pronounced improvement in motor functions (by 42%) and a sharp decrease in the 
number of dyskinesias without any serious side effects. 
The standard treatment for parkinsonism is currently taking the drug, which is 
a precursor of dopamine, a neurotransmitter deficient in this disease. Such drugs 
show an effect only at the initial stages of Parkinson's disease and resistance to 
them develops rapidly. 
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Experimental gene therapy for Parkinson's disease involves a single 
introduction of a lentiviral vector, after which the expression of three genes is 
initiated that encode three key enzymes involved in the biosynthesis of a 
neurotransmitter deficient for such patients. This forces other structures to 
synthesize and release their own dopamine, sensorimotor shell neurons that are not 
affected by Parkinson's disease.  
It is assumed that the introduction of additional copies of the gene responsible 
for the synthesis of GABA, will lead to the normalization of the brain, controlling 
motor functions. 
The first stage of the study of a new method of gene therapy with the 
participation of 12 volunteers was conducted in 2007, and showed the safety of 
this technique. At the second stage, it was supposed to evaluate not only the 
safety, but also the effectiveness of the proposed method of therapy. To do this, 
however, it was necessary to conduct a double-blind, placebo-controlled study, in 
which neither the participants nor the doctors watching them know which 
particular treatment (present or placebo) a particular patient received. It was not 
easy to fulfill these requirements, since the gene therapy drug was injected directly 
into the brain through an opening in the skull. 45 volunteers with Parkinson's 
disease between the ages of 30 and 75 were enrolled for the new study. 22 
participants of the experiment received gene therapy. The rest, who formed the 
control group, also underwent the procedure of drilling a hole in the skull and was 
simulated the introduction of the drug. The hole was not through to reduce the risk 
of complications, but nobody knew about it, except the surgeons who performed 
the manipulation. 
Observation of the subjects lasted for 6 months after the experiment. After 
that, they passed the standard test for assessing motor abilities for patients with 
parkinsonism. In patients who received gene therapy, they improved by an average 
of 23%. In the control group, the improvement averaged 12.7% [3]. 
Thus, the results suggest that Parkinson's disease gene therapy is a safe and 
effective treatment that deserves further research. 
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